Science News
from research organizations

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

Date:
March 16, 2017
Source:
The JAMA Network Journals
Summary:
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study.
Share:
FULL STORY

Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

The advent of intravitreous (in the vitreous, the fluid behind the lens in the eye) anti-vascular endothelial growth factor (VEGF) injections to treat common causes of vision loss, such as exudative (wet) age-related macular degeneration (AMD) and diabetic macular edema has improved visual outcomes for many patients. Intravitreous injections of anti-VEGF agents may increase the risk of elevated intraocular pressure (IOP); however, the risk of developing moderate to advanced glaucoma requiring glaucoma surgery has been unclear.

Brennan D. Eadie, M.D., Ph.D., of the University of British Columbia, Vancouver, and colleagues conducted a study that included patients who had received intravitreous bevacizumab injections for exudative age-related macular degeneration. Cases were identified using glaucoma surgical codes for various procedures. For each case, 10 controls were identified; the number of intravitreous bevacizumab injections received per year was determined for both cases and controls.

Seventy-four cases of glaucoma surgery and 740 controls were identified. The researchers found that seven or more injections were associated with a significantly higher risk of glaucoma surgery.

"Clinicians should be aware of the potential association of repeated, recent intravitreous anti-VEGF injections for diseases, such as exudative AMD, with subsequent need for glaucoma surgery," the authors write.


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. Brennan D. Eadie, Mahyar Etminan, Bruce C. Carleton, David A. Maberley, Frederick S. Mikelberg. Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery. JAMA Ophthalmology, 2017; DOI: 10.1001/jamaophthalmol.2017.0059

Cite This Page:

The JAMA Network Journals. "Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma." ScienceDaily. ScienceDaily, 16 March 2017. <www.sciencedaily.com/releases/2017/03/170316141026.htm>.
The JAMA Network Journals. (2017, March 16). Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma. ScienceDaily. Retrieved May 24, 2017 from www.sciencedaily.com/releases/2017/03/170316141026.htm
The JAMA Network Journals. "Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma." ScienceDaily. www.sciencedaily.com/releases/2017/03/170316141026.htm (accessed May 24, 2017).

RELATED STORIES